Moreover, dual immunotherapy (64.9%) and ICI monotherapy (61.8%) have similar SUCRA values, suggesting that they are equally effective in terms of OS against advanced NSCLC with high PD-L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.